FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP 2002

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE
TOTAL

the CAS Roles thesaurus (/RL field) in this file.

=> s 154486-25-6/rn
5 154486-25-6
0 154486-25-6D
L1 5 154486-25-6/RN
(154486-25-6 (NOTL) 154486-25-6D)

=> d 1-5

L1 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:707018 CAPLUS
DN 133:280556
TI Adjuvant compositions and methods for enhancing immune responses to
polynucleotide-based vaccines
IN Wheeler, Carl J.
PA Vical Incorporated, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2000057917 A2 20001005 WO 2000-US8282 20000324
WO 2000057917 A3 20010104
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
EP 1165140 A2 20020102 EP 2000-919777 20000324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
PRAI US 1999-126340P P 19990326
WO 2000-US8282 W 20000324

L1 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:475564 CAPLUS
DN 133:103732
TI Treatment of viral diseases using an interferon .omega.-expressing
polynucleotide
IN Parker, Suezanne; Horton, Holly
PA Vical Incorporated, USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2000040273 A2 20000713 WO 1999-US30843 19991228
WO 2000040273 A3 20001116
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
PRAI US 1999-115403P P 19990108

L1 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1999:355754 CAPLUS
DN 131:18016
TI Treatment of cancer using cytokine-expressing polynucleotides and
compositions therefor
IN Horton, Holly; Parker, Suezanne; Manthorpe, Marston; Felgner, Philip
PA Vical, Inc., USA
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9926663 A2 19990603 WO 1998-US24830 19981120
WO 9926663 A3 20000106
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
CA 2309766 AA 19990603 CA 1998-2309766 19981120
EP 1032428 A2 20000906 EP 1998-960333 19981120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2001523480 T2 20011127 JP 2000-521864 19981120
PRAI US 1997-67087P P 19971120
US 1998-79914P P 19980330
US 1998-100820P P 19980915
WO 1998-US24830 W 19981120

L1 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1998:351793 CAPLUS
DN 129:36461
TI Complexes of adenovirus with cationic molecules for gene therapy
IN Welsh, Michael J.; Fasbender, Allen J.
PA University of Iowa Research Foundation, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9822144 A2 19980528 WO 1997-US21496 19971120
WO 9822144 A3 19980709
W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5962429 A 19991005 US 1996-755035 19961122
AU 9853615 A1 19980610 AU 1998-53615 19971120
PRAI US 1996-755035 19961122
WO 1997-US21496 19971120

L1 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1996:200633 CAPLUS
DN 124:279113
TI Converting an alcohol to an amine in a cationic lipid dramatically alters
the co-lipid requirement, cellular transfection activity and the
ultrastructure of DNA-cytofectin complexes
AU Wheeler, Carl J.; Sukhu, Loretta; Yang, Gouliang; Tsai, Yali; Bustamente,
Carlos; Felgner, Phil; Norman, Jon; Manthorpe, Marston
CS Vical Incorporated, Suite 100, 9373 Towne Centre Drive, San Diego, CA,
92121, USA
SO Biochimica et Biophysica Acta (1996), 1280(1), 1-11
CODEN: BBACAQ; ISSN: 0006-3002
PB Elsevier
DT Journal
LA English

=> s dmrie/rn
L2 154 DMRIE/RN
(DMRIE)

=> s l2 and vaccine
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L3 19 L2 AND VACCINE

=> s l3 and rsv
2751 RSV
18 RSVS
2754 RSV
(RSV OR RSVS)
L4 1 L3 AND RSV

=> d

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1998:249878 CAPLUS
DN 129:12373
TI Transfection of primary tumor cells and tumor cell lines with plasmid
DNA/lipid complexes
AU Stopeck, Alison T.; Hersh, Evan M.; Brailey, Jacqueline L.; Clark, Paul
R.; Norman, Jon; Parker, Suezanne E.
CS Arizona Cancer Center, Tucson, AZ, 85724-5024, USA
SO Cancer Gene Therapy (1998), 5(2), 119-126
CODEN: CGTHEG; ISSN: 0929-1903
PB Appleton & Lange
DT Journal
LA English

=> d ab

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AB Cancer ***vaccines*** that utilize genetically modified tumor cells
require gene transfer methods capable of producing immunostimulatory doses
of transgenes from fresh or short-term cultures of human tumor cells. Our
studies optimize in vitro transfection of primary tumor cells using
cationic lipids and a plasmid encoding the gene for human interleukin-2
(IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2
than did fresh or short-term tumor cultures as measured by enzyme-linked
immunoabsorbent anal. Importantly, transfection of primary tumor cells
produced immunostimulatory levels of IL-2 as detd. by increased thymidine
incorporation by autologous peripheral blood mononuclear cells and
lymphokine-activated killer cell activity. IL-2 secretion by tumor cells
persisted for at least 30 days post-transfection and was unaffected by .
freeze thawing or irradn. to 8000 rads. Multiple solid tumor types were
successfully transfected, but normal blood mononuclear cells and leukemic
blasts were resistant to transfection. Enzyme-linked immunoabsorbent
anal. of the amt. of IL-2 secreted into the medium by transfected tumor
cells correlated with the percentage of tumor cells expressing
intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a
cytomegalovirus promoter yielded superior transfection efficiencies
compared with plasmids contg. a Rous sarcoma virus promoter. These
results suggest that a clin. ***vaccine*** trial using autologous
tumor cells genetically modified to secrete IL-2 is feasible in patients
with solid tumors.

=> d l kwic

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AB Cancer ***vaccines*** that utilize genetically modified tumor cells
require gene transfer methods capable of producing immunostimulatory doses
of transgenes from fresh or. . . promoter yielded superior transfection
efficiencies compared with plasmids contg. a Rous sarcoma virus promoter.
These results suggest that a clin. ***vaccine*** trial using
autologous tumor cells genetically modified to secrete IL-2 is feasible in
patients with solid tumors.
ST cancer ***vaccine*** transfection IL2 plasmid lipid; cationic lipid
plasmid transfection cancer ***vaccine*** ; interleukin 2 plasmid
transfection cancer ***vaccine*** ; gene therapy cancer interleukin 2
plasmid
IT Promoter (genetic element)
RL: BPR (Biological process); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CMV or ***RSV*** ; primary tumor cell and tumor cell line
transfection with IL-2-encoding plasmid DNA/cationic lipid complexes)
IT ***Vaccines***
(tumor; primary tumor cell and tumor cell line transfection with
IL-2-encoding plasmid DNA/cationic lipid complexes)
IT Antitumor agents
(***vaccines*** ; primary tumor cell and tumor cell line
transfection with IL-2-encoding plasmid DNA/cationic lipid complexes)
IT 2462-63-7, Dope 153312-64-2, ***DMRIE***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primary tumor cell and tumor cell line transfection with IL-2-encoding
plasmid DNA/cationic lipid complexes)

=> d his

(FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP 2002)

FILE 'CAPLUS' ENTERED AT 13:38:15 ON 03 SEP 2002
L1 5 S 154486-25-6/RN
L2 154 S DMRIE/RN
L3 19 S L2 AND VACCINE
L4 1 S L3 AND RSV

=> d l3 1-19 ti so

L3 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Polymer combinations that result in stabilized aerosols for gene delivery
to the lungs
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2

L3 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L3 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Compositions and methods for in vivo delivery of polynucleotide-based
therapeutics
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Improved DNA ***vaccines*** for livestock
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L3 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Highly efficient gene delivery by mRNA electroporation in human
hematopoietic cells: superiority to lipofection and passive pulsing of
mRNA and to electroporation of plasmid cDNA for tumor antigen loading of
dendritic cells
SO Blood (2001), 98(1), 49-56
CODEN: BLOOAW; ISSN: 0006-4971

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Prevention of myocarditis, abortion and intrauterine infection associated
with porcine circovirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L3 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Lipid-nucleic acid compositions for stimulating cytokine secretion and
inducing an immune response
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of renal cell carcinoma by intratumoral administration of an
IL-2 cDNA/ ***DMRIE*** /DOPE lipid complex
SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
CODEN: CUOTFO; ISSN: 1464-8431

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in
vector ***vaccines***
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Feline calicivirus genes and ***vaccines*** , in particular recombined
vaccines
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Porcine circovirus ***vaccine***
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI DNA ***vaccines*** against Paramyxoviridae for pets and game animals
and their delivery in liposomes containing cationic lipids
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

L3 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Cytofectin dimers and methods of use thereof
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

L3 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvant compositions and methods for enhancing immune responses to
polynucleotide-based ***vaccines***
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is
dependent on the sequence and order: A liposome-mediated gene therapy
treatment for bladder cancer
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCREF4; ISSN: 1078-0432

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal
immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMA3; ISSN: 0022-1767

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Direct gene transfer to the respiratory tract of mice with pure plasmid
and lipid-formulated DNA
SO Antisense & Nucleic Acid Drug Development (1998), 8(5), 401-414
CODEN: ANADF5; ISSN: 1087-2906

L3 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2002 ACS
TI Transfection of primary tumor cells and tumor cell lines with plasmid
DNA/lipid complexes
SO Cancer Gene Therapy (1998), 5(2), 119-126
CODEN: CGTHEG; ISSN: 0929-1903

=> d 16-18 ab
1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AB Cancer ***vaccines*** that utilize genetically modified tumor cells
require gene transfer methods capable of producing immunostimulatory doses
of transgenes from fresh or short-term cultures of human tumor cells. Our
studies optimize in vitro transfection of primary tumor cells using
cationic lipids and a plasmid encoding the gene for human interleukin-2
(IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2
than did fresh or short-term tumor cultures as measured by enzyme-linked
immunoabsorbent anal. Importantly, transfection of primary tumor cells
produced immunostimulatory levels of IL-2 as detd. by increased thymidine
incorporation by autologous peripheral blood mononuclear cells and
lymphokine-activated killer cell activity. IL-2 secretion by tumor cells
persisted for at least 30 days post-transfection and was unaffected by
freeze thawing or irradn. to 8000 rads. Multiple solid tumor types were
successfully transfected, but normal blood mononuclear cells and leukemic
blasts were resistant to transfection. Enzyme-linked immunoabsorbent
anal. of the amt. of IL-2 secreted into the medium by transfected tumor
cells correlated with the percentage of tumor cells expressing
intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a
cytomegalovirus promoter yielded superior transfection efficiencies
compared with plasmids contg. a Rous sarcoma virus promoter. These
results suggest that a clin. ***vaccine*** trial using autologous
tumor cells genetically modified to secrete IL-2 is feasible in patients
with solid tumors.

=> d l3 16-18 ab

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
AB A review with 38 refs. discussing the effects of the co-injection of
bupivacaine (BP), polyvinyl pyrollidone (PVP), or ***DMRIE*** :DOPE
cationic liposomes on plasmid DNA-mediated luciferase gene expression and
antibody responses to influenza nucleoprotein (NP) antigen.

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
AB The development of ***vaccines*** against pathogens transmitted across
the genito-rectal mucosa that effectively stimulate both secretory IgA Abs
and cytotoxic T lymphocytes in the genital tract and CTL in the draining
lymph nodes (LN) has proven a major challenge. Here we report a novel,
noninvasive approach of genetic vaccination via the intranasal route.
Such vaccination elicits immune responses in the genital and rectal
mucosa, draining LNs, and central lymphoid system. Intranasal
immunization with plasmid DNA-lipid complexes encoding the model Ag
firefly luciferase resulted in dissemination of the DNA and the encoded
transcript throughout the respiratory and gastrointestinal tracts,
draining LNs, and spleen. Complexing the plasmid DNA with the lipid
DMRIE /DOPE enhanced expression of the encoded protein in the
respiratory tract, increased specific secretory IgA Ab in the vaginal and
rectal tracts, and increased the circulating levels of specific IgA and
IgG. In addn., intranasal DNA immunization resulted in generation of
Ag-specific CTL that were localized in the genital and cervical LNs and
spleen. These results suggest that intranasal immunization with plasmid
DNA-lipid complexes may represent a generic immunization strategy against
pathogens transmitted across the genito-rectal and other mucosal surfaces.

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
AB Direct gene transfer into the respiratory system could be carried out for
either therapeutic or immunization purposes. Here we demonstrate that
cells in the lung can take up and express plasmid DNA encoding a
luciferase reporter gene whether it is administered in naked form or
formulated with cationic liposomes. Depending on the lipid used, the
transfection efficiency with liposome-formulated DNA may be higher, the
same as, or less than that with pure plasmid DNA.
Tetramethyltetraalkylspermine analogs with alkyl groups of 16 or 18
carbons and ***DMRIE*** /cholesterol formulations proved particularly
effective. Similar results for reporter gene expression in the lung were
obtained whether the DNA (naked or lipid formulated) was administered by
indirect, non-invasive intranasal delivery (inhaled or instilled) or by
invasive, direct intratracheal delivery (injected or via a cannula).
Reporter gene expression peaks around 4 days, then falls off dramatically
by 9 days. The dose-response is linear, at least up to 100 .mu.g plasmid
DNA, suggesting better transfection efficiencies might be realized if
there was not a vol. limitation. For a given dose of DNA, the best
results are obtained when the DNA is mixed with the min. amt. of lipid
that can complex it completely. These results are discussed in the
context of direct gene transfer for either gene therapy or delivery of a
mucosal DNA ***vaccine*** .

=> s 153312-4-2/rn or 154486-25-6/rn
0 153312-4-2/RN
(153312-4-2)
5 154486-25-6
0 154486-25-6D
5 154486-25-6/RN
(154486-25-6 (NOTL) 154486-25-6D)
L5 5 153312-4-2/RN OR 154486-25-6/RN

=> s 153312-64-2/rn or 154486-25-6/rn
111 153312-64-2
6 153312-64-2D
105 153312-64-2/RN
(153312-64-2 (NOTL) 153312-64-2D)
5 154486-25-6
0 154486-25-6D
5 154486-25-6/RN
(154486-25-6 (NOTL) 154486-25-6D)
L6 105 153312-64-2/RN OR 154486-25-6/RN

=> s l6 and (rsv or brsv)
2751 RSV
18 RSVS
2754 RSV
(RSV OR RSVS)
110 BRSV
1 BRSVS
110 BRSV
(BRSV OR BRSVS)
L7 5 L6 AND (RSV OR BRSV)

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 4 DUP REM L7 (1 DUPLICATE REMOVED)

=> d 1-4 ti so

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Transfection of primary tumor cells and tumor cell lines with plasmid
DNA/lipid complexes
SO Cancer Gene Therapy (1998), 5(2), 119-126
CODEN: CGTHEG; ISSN: 0929-1903

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
TI Cationic liposome-mediated expression of HIV-regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or expressing HIV
SO Biochimica et Biophysica Acta (1997), 1356(2), 185-197
CODEN: BBACAQ; ISSN: 0006-3002

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Plasmids suitable for gene therapy
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Enhanced gene delivery and mechanism studies with a novel series of
cationic lipid formulations
SO J. Biol. Chem. (1994), 269(4), 2550-61
CODEN: JBCHA3; ISSN: 0021-9258

=> d l-4 ab

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
AB Cancer vaccines that utilize genetically modified tumor cells require gene
transfer methods capable of producing immunostimulatory doses of
transgenes from fresh or short-term cultures of human tumor cells. Our
studies optimize in vitro transfection of primary tumor cells using
cationic lipids and a plasmid encoding the gene for human interleukin-2
(IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2
than did fresh or short-term tumor cultures as measured by enzyme-linked
immunoabsorbent anal. Importantly, transfection of primary tumor cells
produced immunostimulatory levels of IL-2 as detd. by increased thymidine
incorporation by autologous peripheral blood mononuclear cells and
lymphokine-activated killer cell activity. IL-2 secretion by tumor cells
persisted for at least 30 days post-transfection and was unaffected by
freeze thawing or irradn. to 8000 rads. Multiple solid tumor types were
successfully transfected, but normal blood mononuclear cells and leukemic
blasts were resistant to transfection. Enzyme-linked immunoabsorbent
anal. of the amt. of IL-2 secreted into the medium by transfected tumor
cells correlated with the percentage of tumor cells expressing
intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a
cytomegalovirus promoter yielded superior transfection efficiencies
compared with plasmids contg. a Rous sarcoma virus promoter. These
results suggest that a clin. vaccine trial using autologous tumor cells
genetically modified to secrete IL-2 is feasible in patients with solid
tumors.

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
AB HIV-regulated expression of the diphtheria toxin A fragment gene
(HIV-DT-A) is a potential gene therapy approach to AIDS. Since cationic
liposomes are safe and non-immunogenic for in vivo gene delivery, the
authors examd. whether LipofectAMINE or DMRIE reagent could mediate the
transfection of HIV-DT-A (pTHA43) or the HIV-regulated luciferase gene
(pLUCA43) into HIV-infected or uninfected HeLa cells. PLUCA43 was
expressed at a 103-fold higher level in HeLa/LAV cells than in uninfected
HeLa cells, while the extent of expression of ***RSV*** -regulated
luciferase was the same in both cell lines. Co-transfection of HeLa cells
with pTHA43 and the proviral HIV clone, HXB.DELTA.Bgl, resulted in
complete inhibition of virus prodn. In contrast, the delivery of HIV-DT-A
to chronically infected HeLa/LAV or HeLa/IIIB cells, or to HeLa CD4+ cells
before infection, did not have a specific effect on virus prodn., since
treatment of cells with control plasmids also reduced virus prodn. This
redn. could be ascribed to cytotoxicity of the reagents. The efficiency
of transfection, as measured by the percentage of cells expressing
.beta.-gal, was .apprx.5. Thus, cationic liposome-mediated transfection
was too inefficient to inhibit virus prodn. when the DT-A was delivered by
cationic liposomes to chronically- or de novo-infected cells. However,
when both the virus and DT-A genes were delivered into the same cells by
cationic liposomes, DT-A was very effective at inhibiting virus prodn.
The results indicate that the successful use of cationic liposomes for
gene therapy will require the improvement of their transfection
efficiency.

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
AB The invention provides vectors adapted for use in transferring into tissue
or cells of an organism genetic mater. encoding one or more cistrons
capable of expressing one or more immunogenic or therapeutic peptides and
related methods. Prepn. of a HLA-B7-encoding plasmid that contains the
origin of replication of pBR322, the ***RSV*** LTR promoter, SV40
polyadenylation signal, etc., methods for transfection using cationic
lipid formulations comprising DMRIE/DOPE, and its use in gene therapy are
also described.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
AB Studies are reported which examd. the effects of some systematic chem.
structural changes in both the cationic amphiphile and the neutral
phospholipid components of liposomes on their biol. activity. Cationic
and neutral phospholipids were formulated together as large multilamellar
vesicles or small sonicated unilamellar vesicles in water, and each
formulation was assayed quant. in 96-well microtiter plates under 64
different assay conditions using COS.7 cells and an ***RSV***
-.beta.-galactosidase expression plasmid. The cationic lipid mols. used
were derived from a novel series of 2,3-dialkytoxypropyl quaternary
ammonium compds. contg. a hydroxyalkyl moiety on the quaternary amine. A
homologous series of dioleylalkyl (C18:1) compds. contg. increasing
hydroxyalkyl chain lengths on the quaternary amine were formulated with 50
mol % dioleoylphosphatidylethanolamine (DOPE) and assayed for transfection
activity. The order of efficacy was Et > Pr > Bu > pentyl >
2,3-dioleyloxypropyl-1-trimethyl ammonium bromide (DOTMA). The order of
transfection efficacy for a similarly formulated homologous series of
hydroxyethyl quaternary ammonium derivs. with different alkyl chain
substitutions was dimyristyl > dioleyl > dipalmityl > disteryl. Addn. of
100 .mu.M chloroquine in the transfection expt. enhanced the activity of
the dioleyl compd. by 4-fold and decreased the activity of the dimyristyl
compd. by 70%. For each of the compds. and formulations examd., large
multilamellar vesicles were more active than small unilamellar vesicles.
The neutral phospholipid requirements for transfection were also examd.
Cationic vesicles formulated with 50 mol % DOPE were 2-5-fold more active
than formulations with 50 mol % dioleoylphosphatidylcholine or
formulations without any neutral lipid, and the level of DOPE required for
optimal activity was 50 mol %. DOPE analogs with increasing acyl chain
satn. were progressively less active than unsatd. analogs; analogs with
increasing nos. of Me or methylene groups added to the primary amine were
also progressively less active. The lysophosphatidylethanolamine analogs
examd. neither enhanced nor inhibited the activity of these reagents.
These results have implications regarding the design of new cationic and
neutral lipid mols. for use in the development of improved cationic lipid
gene delivery vectors.

=> d 3

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 1995:468608 CAPLUS
DN 123:102768
TI Plasmids suitable for gene therapy
IN Nabel, Gary J.; Nabel, Elizabeth G.; Lew, Denise; Marquet, Magda
PA Vical Inc., USA; Regents of the University of Michigan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9429469	A2	19941222	WO 1994-US6069	19940527
WO 9429469	A3	19950323		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 702722	A1	19960327	EP 1994-919290	19940527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5910488	A	19990608	US 1995-564313	19951201
PRAI US 1993-74344		19930607		
WO 1994-US6069		19940527		

=> s RSV (S) vaccine
2751 RSV
18 RSVS
2754 RSV
(RSV OR RSVS)
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L9 191 RSV (S) VACCINE

=> s l9 and (bovine or cow)
140352 BOVINE
541 BOVINES
140703 BOVINE
(BOVINE OR BOVINES)
28401 COW
28351 COWS
45109 COW
(COW OR COWS)
L10 21 L9 AND (BOVINE OR COW)

=> d 1-21 ti so

L10 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Non-glycosylated peptides derived from the G attachment glycoprotein of
respiratory syncytial virus for use as antigens in vaccines
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2

L10 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host
range determinants: a chimeric ***bovine*** RSV with NS genes from
human RSV is attenuated in interferon-competent ***bovine*** cells
SO Journal of Virology (2002), 76(9), 4287-4293
CODEN: JOVIAM; ISSN: 0022-538X

L10 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Mucosal immunization of rhesus monkeys against respiratory syncytial virus
subgroups A and B and human parainfluenza virus type 3 by using a live
cDNA-derived vaccine based on a host range-attenuated ***bovine***
parainfluenza virus type 3 vector backbone
SO Journal of Virology (2002), 76(3), 1089-1099
CODEN: JOVIAM; ISSN: 0022-538X

L10 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Respiratory syncytial virus vaccines expressing protective antigens from
promotor-proximal genes
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2

L10 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Formation of infectious respiratory syncytial virus particles by
expression of cloned viral genes
SO U.S., 24 pp.
CODEN: USXXAM

L10 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Production of attenuated, human- ***bovine*** chimeric respiratory
syncytial virus vaccines
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L10 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Attenuated respiratory syncytial virus vaccines involving modification of
M2 ORF2
SO PCT Int. Appl., 124 pp.

CODEN: PIXXD2

L10 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Plant-derived antigens against respiratory syncytial virus
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2

L10 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Production of attenuated chimeric respiratory syncytial virus vaccines
from cloned nucleotide sequences
SO PCT Int. Appl., 280 pp.
CODEN: PIXXD2

L10 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Chimeric ***bovine*** respiratory syncytial virus with glycoprotein
gene substitutions from human respiratory syncytial virus (HRSV): effects
on host range and evaluation as a live-attenuated HRSV vaccine
SO Journal of Virology (2000), 74(3), 1187-1199
CODEN: JOVIAM; ISSN: 0022-538X

L10 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Identification of a conserved neutralization site in the first heptad
repeat of the fusion protein of respiratory syncytial virus
SO Archives of Virology (1998), 143(2), 313-320
CODEN: ARVIDF; ISSN: 0304-8608

L10 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both
coding for the G protein of BRSV
SO Vaccine (1997), 15(17/18), 1908-1916
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Recombinant vaccinia viruses expressing the F, G or N, but not the M2,
protein of ***bovine*** respiratory syncytial virus (BRSV) induce
resistance to BRSV challenge in the calf and protect against the
development of pneumonic lesions
SO Journal of General Virology (1997), 78(12), 3195-3206
CODEN: JGVIAY; ISSN: 0022-1317

L10 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI In vivo and vitro packaging of infectious respiratory syncytial virus
using cloned viral nucleic acids
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2

L10 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Phosphoprotein profile analysis of ruminant respiratory syncytial virus
isolates
SO American Journal of Veterinary Research (1997), 58(5), 478-481
CODEN: AJVRAH; ISSN: 0002-9645

L10 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Stabilization of respiratory syncytial virus (***RSV***) against
thermal inactivation and freeze-thaw cycles for development and control of
RSV ***vaccines*** and immune globulin
SO Vaccine (1996), 14(15), 1417-1420
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Immune responses of lambs to the fusion (F) glycoprotein of ***bovine***
respiratory syncytial virus expressed on insect cells infected with a
recombinant baculovirus
SO Vaccine (1996), 14(8), 773-779
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Antigenic peptides derived from the G protein of respiratory syncytial
virus for type- and subtype-specific diagnosis of infection
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L10 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI A cold-passaged, attenuated strain of human respiratory syncytial virus
contains mutations in the F and L genes
SO Virology (1995), 208(2), 478-84
CODEN: VIRLAX; ISSN: 0042-6822

L10 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Human respiratory syncytial virus vaccine derived from the 1A (9.5 kd)
protein
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2

L10 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2002 ACS
TI Murine cytotoxic T cells specific to respiratory syncytial virus recognize
different antigenic subtypes of the virus
SO J. Gen. Virol. (1986), 67(4), 623-9
CODEN: JGVIAY; ISSN: 0022-1317

=> d l3 ab

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002 ACS
AB The immunogenicity and protective efficacy of recombinant vaccinia viruses
(rVV) encoding the F, G, N, or M2 (22K) proteins of ***bovine***
respiratory syncytial virus (BRSV) were evaluated in calves, the natural
host for BRSV. Calves were vaccinated either by scarification or
intratracheally with rVV and challenged 6-7 wk later with BRSV. Although
replication of rVV expressing the F protein in the respiratory tract was
limited after intratracheal vaccination, the levels of serum and pulmonary
antibody were similar to those induced following scarification. The serum
antibody response induced by the F protein was biased in favor of IgG1
antibody, whereas the G and the N proteins induced similar levels of
IgG1:IgG2, and antibody was undetectable in calves primed with the M2
protein. The F protein induced neutralizing antibodies, but only levels
of complement-dependent neutralizing antibodies were induced by the G
protein, and antibody induced by the N protein was not neutralizing. The
F and N proteins primed calves for BRSV-specific lymphocyte proliferative
responses, whereas proliferative responses were detected in calves primed
with the G protein only after BRSV challenge. The M2 protein primed
lymphocytes in only 1 out of 5 calves. Although there were differences in
the immune responses induced by the rVVs, the F, G and N, but not the M2,
proteins induced protection against BRSV infection and, in contrast with
the enhanced lung pathol. seen in mice vaccinated with rVV expressing
individual proteins of human RSV, there was a redn. in lung pathol. in
calves.

=> d l3

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002 ACS
AN 1997:775451 CAPLUS
DN 128:60477
TI Recombinant vaccinia viruses expressing the F, G or N, but not the M2,
protein of ***bovine*** respiratory syncytial virus (BRSV) induce
resistance to BRSV challenge in the calf and protect against the
development of pneumonic lesions
AU Taylor, Geraldine; Thomas, Lewis H.; Furze, Julie M.; Cook, Roy S.; Wyld,
Sara G.; Lerch, Robert; Hardy, Richard; Wertz, Gail W.
CS Institute for Animal Health, Newbury, RG20 7NN, UK
SO Journal of General Virology (1997), 78(12), 3195-3206
CODEN: JGVIAY; ISSN: 0022-1317
PB Society for General Microbiology
DT Journal
LA English

=> s DOPE/rn
4692 DOPE
1033 DOPES
L11 5248 DOPE/RN
(DOPE OR DOPES)

=> s l11 and DMRIE/rn
154 DMRIE/RN
(DMRIE)
L12 83 L11 AND DMRIE/RN

=> s l12 and vaccine
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L13 14 L12 AND VACCINE

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 14 DUP REM L13 (0 DUPLICATES REMOVED)

=> d 1-14 ti so

L14 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L14 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Compositions and methods for in vivo delivery of polynucleotide-based
therapeutics
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2

L14 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Improved DNA ***vaccines*** for livestock
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L14 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Prevention of myocarditis, abortion and intrauterine infection associated
with porcine circovirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L14 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in
vector ***vaccines***
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L14 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Feline calicivirus genes and ***vaccines*** , in particular recombined
vaccines
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2

L14 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of renal cell carcinoma by intratumoral administration of an
IL-2 cDNA/ ***DMRIE*** / ***DOPE*** lipid complex
SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
CODEN: CUOTFO; ISSN: 1464-8431

L14 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Porcine circovirus ***vaccine***
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L14 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI DNA ***vaccines*** against Paramyxoviridae for pets and game animals
and their delivery in liposomes containing cationic lipids
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

L14 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvant compositions and methods for enhancing immune responses to
polynucleotide-based ***vaccines***
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L14 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is
dependent on the sequence and order: A liposome-mediated gene therapy
treatment for bladder cancer
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCREF4; ISSN: 1078-0432

L14 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L14 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal
immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMA3; ISSN: 0022-1767

L14 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS
TI Transfection of primary tumor cells and tumor cell lines with plasmid
DNA/lipid complexes

SO Cancer Gene Therapy (1998), 5(2), 119-126
CODEN: CGTHEG; ISSN: 0929-1903

=> d 12 ab

L14 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS
AB A review with 38 refs. discussing the effects of the co-injection of
bupivacaine (BP), polyvinyl pyrollidone (PVP), or ***DMRIE*** :
DOPE cationic liposomes on plasmid DNA-mediated luciferase gene
expression and antibody responses to influenza nucleoprotein (NP) antigen.

=> s DMRIE:DOPE
154 DMRIE
4692 DOPE
1033 DOPES
5248 DOPE
(DOPE OR DOPES)
L15 42 DMRIE:DOPE
(DMRIE(W)DOPE)

=> s l15 and vaccine
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L16 4 L15 AND VACCINE

=> d l1-4 ti so

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Prevention of myocarditis, abortion and intrauterine infection associated
with porcine circovirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of renal cell carcinoma by intratumoral administration of an
IL-2 cDNA/ ***DMRIE*** / ***DOPE*** lipid complex
SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
CODEN: CUOTFO; ISSN: 1464-8431

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
TI Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal
immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMA3; ISSN: 0022-1767

=> d 4 ab

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
AB The development of ***vaccines*** against pathogens transmitted across
the genito-rectal mucosa that effectively stimulate both secretory IgA Abs
and cytotoxic T lymphocytes in the genital tract and CTL in the draining
lymph nodes (LN) has proven a major challenge. Here we report a novel,
noninvasive approach of genetic vaccination via the intranasal route.
Such vaccination elicits immune responses in the genital and rectal
mucosa, draining LNs, and central lymphoid system. Intranasal
immunization with plasmid DNA-lipid complexes encoding the model Ag
firefly luciferase resulted in dissemination of the DNA and the encoded
transcript throughout the respiratory and gastrointestinal tracts,
draining LNs, and spleen. Complexing the plasmid DNA with the lipid
DMRIE / ***DOPE*** enhanced expression of the encoded protein in
the respiratory tract, increased specific secretory IgA Ab in the vaginal
and rectal tracts, and increased the circulating levels of specific IgA
and IgG. In addn., intranasal DNA immunization resulted in generation of
Ag-specific CTL that were localized in the genital and cervical LNs and
spleen. These results suggest that intranasal immunization with plasmid
DNA-lipid complexes may represent a generic immunization strategy against
pathogens transmitted across the genito-rectal and other mucosal surfaces.

=> d 4

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 1999:32735 CAPLUS
DN 130:195479
TI Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal
immunity in the female genital and rectal tracts
AU Klavinskis, Linda S.; Barnfield, Christina; Gao, Liquan; Parkert, Suezanne
CS Department of Immunobiology, Guy's Kings College and St. Thomas' Medical
and Dental Schools, London, SE1 9RT, UK
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=> s DMRIE and DOPE and delivery
154 DMRIE
4692 DOPE
1033 DOPES
5248 DOPE
(DOPE OR DOPES)
122097 DELIVERY
1277 DELIVERIES
122908 DELIVERY
(DELIVERY OR DELIVERIES)
L17 53 DMRIE AND DOPE AND DELIVERY

=> dup rem l17
PROCESSING COMPLETED FOR L17
L18 52 DUP REM L17 (1 DUPLICATE REMOVED)

=> s l17 and vaccine
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L19 7 L17 AND VACCINE

=> d 1-7

L19 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2002:10302 CAPLUS
DN 136:74555
TI ***Vaccine*** against foot-and-mouth disease
IN King, Andrew; Burman, Alison; Audonnet, Jean-Christophe; Lombard, Michel
PA Merial, Fr.
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000251	A1	20020103	WO 2001-FR2042	20010627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
FR 2810888 A1 20020104 FR 2000-8437 20000629
AU 2001070678 A5 20020108 AU 2001-70678 20010627
PRAI FR 2000-8437 A 20000629
WO 2001-FR2042 W 20010627
OS MARPAT 136:74555
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2001:798084 CAPLUS
DN 135:348865
TI Compositions and methods for in vivo ***delivery*** of
polynucleotide-based therapeutics
IN Hartikka, Jukka; Sukhu, Loretta; Manthorpe, Marston
PA Vical Incorporated, USA
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001080897	A2	20011101	WO 2001-US12975	20010423

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR
US 2002019358 A1 20020214 US 2001-839574 20010423
PRAI US 2000-198823P P 20000421
US 2000-253153P P 20001128

L19 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2001:101291 CAPLUS
DN 134:161880
TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in
vector ***vaccines***
IN Hermanson, Gary George
PA Vical Inc., USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001009303	A2	20010208	WO 2000-US20679	20000731
WO 2001009303	A3	20010816		

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI US 1999-146170P P 19990730

L19 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2000:900679 CAPLUS
DN 134:55491
TI DNA ***vaccines*** against Paramyxoviridae for pets and game animals
and their ***delivery*** in liposomes containing cationic lipids
IN Fischer, Laurent Jean-Charles; Barzu-le, Roux Simona; Audonnet, Jean-Christophe Francis
PA Merial, Fr.
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000077043	A2	20001221	WO 2000-FR1592	20000608
WO 2000077043	A3	20010719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
FR 2794648 A1 20001215 FR 1999-7604 19990610
BR 2000011732 A 20020305 BR 2000-11732 20000608
EP 1185662 A2 20020313 EP 2000-940474 20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRAI FR 1999-7604 A 19990610
US 1999-144490P P 19990719
WO 2000-FR1592 W 20000608
OS MARPAT 134:55491

L19 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2000:707018 CAPLUS
DN 133:280556
TI Adjuvant compositions and methods for enhancing immune responses to
polynucleotide-based ***vaccines***
IN Wheeler, Carl J.
PA Vical Incorporated, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2000057917 A2 20001005 WO 2000-US8282 20000324
WO 2000057917 A3 20010104
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 1165140 A2 20020102 EP 2000-919777 20000324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
PRAI US 1999-126340P P 19990326
WO 2000-US8282 W 20000324

L19 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2000:573482 CAPLUS
DN 134:146025
TI Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated gene therapy treatment for bladder cancer
AU Larchian, William A.; Horiguchi, Yutaka; Nair, Smita K.; Fair, William R.; Heston, Warren D. W.; Gilboa, Eli
CS Department of Urology, The Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCREF4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 1999:679109 CAPLUS
DN 132:164839
TI Adjuvants for plasmid DNA ***vaccines***
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela; Manthorpe, Marston
CS Vical Inc., San Diego, CA, USA
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN
PB Humana Press Inc.
DT Journal; General Review
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 7 ab

L19 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS
AB A review with 38 refs. discussing the effects of the co-injection of bupivacaine (BP), polyvinyl pyrollidone (PVP), or ***DMRIE*** : ***DOPE*** cationic liposomes on plasmid DNA-mediated luciferase gene expression and antibody responses to influenza nucleoprotein (NP) antigen.

=> d his

(FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP 2002)

FILE 'CAPLUS' ENTERED AT 13:38:15 ON 03 SEP 2002
L1 5 S 154486-25-6/RN
L2 154 S DMRIE/RN
L3 19 S L2 AND VACCINE
L4 1 S L3 AND RSV
L5 5 S 153312-4-2/RN OR 154486-25-6/RN
L6 105 S 153312-64-2/RN OR 154486-25-6/RN
L7 5 S L6 AND (RSV OR BRSV)
L8 4 DUP REM L7 (1 DUPLICATE REMOVED)
L9 191 S RSV (S) VACCINE
L10 21 S L9 AND (BOVINE OR COW)
L11 5248 S DOPE/RN
L12 83 S L11 AND DMRIE/RN
L13 14 S L12 AND VACCINE
L14 14 DUP REM L13 (0 DUPLICATES REMOVED)
L15 42 S DMRIE:DOPE
L16 4 S L15 AND VACCINE
L17 53 S DMRIE AND DOPE AND DELIVERY
L18 52 DUP REM L17 (1 DUPLICATE REMOVED)
L19 7 S L17 AND VACCINE

=> s l17 and (vaccine or gene delivery or gene therapy)
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
717656 GENE
270831 GENES
759543 GENE
(GENE OR GENES)
122097 DELIVERY
1277 DELIVERIES
122908 DELIVERY
(DELIVERY OR DELIVERIES)
3749 GENE DELIVERY
(GENE(W)DELIVERY)
717656 GENE
270831 GENES
759543 GENE
(GENE OR GENES)
175374 THERAPY
10179 THERAPIES
180867 THERAPY
(THERAPY OR THERAPIES)
25288 GENE THERAPY
(GENE(W)THERAPY)
L20 34 L17 AND (VACCINE OR GENE DELIVERY OR GENE THERAPY)

=> d 1-20 ti so

L20 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Transfection with fluorinated lipoplexes based on fluorinated analogues of DOTMA, ***DMRIE*** and DPPES
SO Biochimica et Biophysica Acta (2002), 1564(2), 349-358
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L20 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Compositions and methods for in vivo ***delivery*** of polynucleotide-based therapeutics
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2

L20 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI High-throughput screening method for identification of new lipofection reagents
SO Journal of Biomolecular Screening (2001), 6(4), 245-254
CODEN: JBISF3; ISSN: 1087-0571

L20 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/.beta.2-microglobulin DNA-liposome complex, in patients with metastatic melanoma
SO Clinical Cancer Research (2001), 7(8), 2285-2291
CODEN: CCREF4; ISSN: 1078-0432

L20 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Leuvectin(Vical Inc)
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2001), 2(7), 976-981
CODEN: COIDAZ

L20 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Efficiency and Toxicity of Liposome-mediated Gene Transfer to Corneal Endothelial Cells
SO Experimental Eye Research (2001), 73(1), 1-7
CODEN: EXERA6; ISSN: 0014-4835

L20 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Intervesical interleukin-2 ***gene*** ***therapy*** in orthotopic mouse model of bladder cancer
SO Keio Igaku (2001), 78(2), T177-T187
CODEN: KEIGAS; ISSN: 0368-5179

L20 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in vector ***vaccines***
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L20 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Peptide-lipid conjugates, liposomes and liposomal drug ***delivery***
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

L20 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI DNA ***vaccines*** against Paramyxoviridae for pets and game animals and their ***delivery*** in liposomes containing cationic lipids
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

L20 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Novel compositions useful for delivering anti-inflammatory agents into a cell
SO Eur. Pat. Appl., 78 pp.
CODEN: EPXXDW

L20 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based ***vaccines***
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L20 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated ***gene*** ***therapy*** treatment for bladder cancer
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCREF4; ISSN: 1078-0432

L20 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Intravesical liposome-mediated interleukin-2 ***gene*** ***therapy*** in orthotopic murine bladder cancer model
SO Gene Therapy (2000), 7(10), 844-851
CODEN: GETHEC; ISSN: 0969-7128

L20 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin A genes in HeLa cells infected with or expressing HIV
SO Biochimica et Biophysica Acta (1997), 1356(2), 185-197
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Dry-powder compositions and methods for nucleic acid ***delivery*** to the lung
SO U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 417,507, abandoned.
CODEN: USXXAM

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
SO U.S., 63 pp., Cont.-in-part of U.S. 5,705,385.
CODEN: USXXAM

L20 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L20 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Plasmids suitable for antitumor ***gene*** ***therapy***
SO U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 74,344, abandoned.
CODEN: USXXAM

=> d 18

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1999:704853 CAPLUS
DN 131:314184
TI Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
IN Wheeler, Jeffery J.; Bally, Marcel B.; Zhang, Yuan-Peng; Reimer, Dorothy L.; Hope, Michael; Cullis, Pieter R.; Scherrer, Peter
PA Inex Pharmaceuticals Corp., Can.
SO U.S., 63 pp., Cont.-in-part of U.S. 5,705,385.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 5976567 A 19991102 US 1996-660025 19960606
US 5705385 A 19980106 US 1995-485458 19950607
US 5981501 A 19991109 US 1995-484282 19950607
CA 2222328 AA 19961219 CA 1996-2222328 19960606
PRAI US 1995-484282 A2 19950607
US 1995-485458 A2 19950607
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 d 21-34 ti so
'D' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ——— GI and AB
ALL ——— BIB, AB, IND, RE
APPS ——— AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN ——— List of CA abstract numbers without answer numbers
CBIB ——— AN, plus Compressed Bibliographic Data
DALL --------- ALL, delimited (end of each field identified)
DMAX --------- MAX, delimited for post-processing
FAM ---------- AN, PI and PRAI in table, plus Patent Family data
FBIB ——— AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS ——— PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN ——— CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS ——— ABS, indented with text labels
IALL ——— ALL, indented with text labels
IBIB --------- BIB, indented with text labels
IMAX --------- MAX, indented with text labels
ISTD ——— STD, indented with text labels

OBIB ——— AN, plus Bibliographic Data (original)
OIBIB ——— OBIB, indented with text labels

SBIB ——— BIB, no citations
SIBIB ——— IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ——— HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ——— First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ——— First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC --------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO. You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ti

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid
complex intermediate and use for gene transfer

L20 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of established tumors in mice by intratumoral injection of
interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Construction of cationic lipid complex-polynucleotides-contg.liposomes for
gene ***delivery*** to mucosal epithelium for immunization or
therapeutic purposes

L20 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Dry powder formulations of polynucleotide complexes for inhalation
delivery to the respiratory tract

L20 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Enhanced in vitro and in vivo ***gene*** ***delivery*** using
cationic agent complexed retrovirus vectors

L20 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Electrostatic parameters of cationic liposomes commonly used for
gene ***delivery*** as determined by 4-heptadecyl-7-
hydroxycoumarin

L20 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Cationic liposome-mediated expression of HIV-regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or expressing HIV

L20 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Pulmonary surfactant inhibits cationic liposome-mediated ***gene***
delivery to respiratory epithelial cells in vitro

L20 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Stabilization of polynucleotide complexes

L20 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Separation of active complexes from mixtures of polynucleotides associated
with transfecting components

L20 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Single-vial formulations of DNA/lipid complexes

L20 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI A new cationic liposome DNA complex enhances the efficiency of arterial
gene transfer in vivo

L20 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI ***Delivery*** of DNA-cationic liposome complexes by small-particle
aerosol

L20 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Cancer ***gene*** ***therapy*** using plasmid DNA: safety
evaluation in rodents and non-human primates

L20 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Safety and short-term toxicity of a novel cationic lipid formulation for
human ***gene*** ***therapy***

=> d 21-34 ti so

L20 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of established tumors in mice by intratumoral injection of
interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity
SO Cancer Gene Therapy (1998), 5(5), 321-330
CODEN: CGTHEG; ISSN: 0929-1903

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Construction of cationic lipid complex-polynucleotides-contg.liposomes for
gene ***delivery*** to mucosal epithelium for immunization or
therapeutic purposes
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2

L20 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Dry powder formulations of polynucleotide complexes for inhalation
delivery to the respiratory tract
SO U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 482,110.
CODEN: USXXAM

L20 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Enhanced in vitro and in vivo ***gene*** ***delivery*** using
cationic agent complexed retrovirus vectors
SO Gene Therapy (1998), 5(9), 1180-1186
CODEN: GETHEC; ISSN: 0969-7128

L20 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Electrostatic parameters of cationic liposomes commonly used for
gene ***delivery*** as determined by 4-heptadecyl-7-
hydroxycoumarin
SO Biochimica et Biophysica Acta (1997), 1329(2), 211-222
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Cationic liposome-mediated expression of HIV-regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or expressing HIV
SO Biochimica et Biophysica Acta (1997), 1356(2), 185-197
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Pulmonary surfactant inhibits cationic liposome-mediated ***gene***
delivery to respiratory epithelial cells in vitro
SO Human Gene Therapy (1997), 8(4), 431-438
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Stabilization of polynucleotide complexes
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

L20 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Separation of active complexes from mixtures of polynucleotides associated
with transfecting components
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2

L20 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Single-vial formulations of DNA/lipid complexes
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

L20 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI A new cationic liposome DNA complex enhances the efficiency of arterial
gene transfer in vivo
SO Human Gene Therapy (1996), 7(15), 1803-1812
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI ***Delivery*** of DNA-cationic liposome complexes by small-particle
aerosol
SO Human Gene Therapy (1996), 7(6), 731-741
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Cancer ***gene*** ***therapy*** using plasmid DNA: safety
evaluation in rodents and non-human primates
SO Human Gene Therapy (1995), 6(5), 575-90
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Safety and short-term toxicity of a novel cationic lipid formulation for
human ***gene*** ***therapy***
SO Hum. Gene Ther. (1993), 4(6), 781-8
CODEN: HGTHE3; ISSN: 1043-0342

=> d 22

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1998:621321 CAPLUS
DN 129:235638
TI Construction of cationic lipid complex-polynucleotides-contg.liposomes for
gene ***delivery*** to mucosal epithelium for immunization or
therapeutic purposes
IN Davis, Heather Lynn; Jessee, Joel; Gebeyehu, Gulilat
PA Can.
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9840499	A1	19980917	WO 1997-US3421	19970310
AU 9719871	A1	19980929	AU 1997-19871	19970310

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI WO 1997-US3421 19970310

=> d 22 ab

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002 ACS
AB Disclosed are compns. and method for transfecting mammalian mucosal
epithelia with nucleic acid/cationic lipid complexes. The nucleic
acid/cationic lipid complexes may be administered, for example,
intranasally or directly into the lungs. The best results are obtained
when the lipid mixed with the max. amt. of DNA that it can complex. Thus,
cationic lipids are complexed with a polynucleotides coding for
immunogenic antigens in mice. Hybridomas are constructed by fusing
B-lymphocytes with myeloma cells, and pos. clones are selected which
produce anti-immunogen antibody. Suitable cationic lipids include DOTMA,
DOTAP, and DORI-esters. Neutral lipids that can be used include
lecithins, phosphotidylethanolamine, phosphatidylethanolamines (e.g.
DOPE , OPPE), and distearoylphosphatidylethanolamine. Cationic
sterol derivs., such as DC-Chol can also be used. Polyclonal and
monoclonal antibodies and antisense oligonucleotides are also claimed
effective to ***gene*** ***therapy*** . The method is tested in a
mouse system.

=> d 22 kwic

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002 ACS
TI Construction of cationic lipid complex-polynucleotides-contg.liposomes for
gene ***delivery*** to mucosal epithelium for immunization or
therapeutic purposes
AB . . . antibody. Suitable cationic lipids include DOTMA, DOTAP, and
DORI-esters. Neutral lipids that can be used include lecithins,
phosphotidylethanolamine, phosphatidylethanolamines (e.g. ***DOPE*** ,
OPPE), and distearoylphosphatidylethanolamine. Cationic sterol derivs.,
such as DC-Chol can also be used. Polyclonal and monoclonal antibodies
and antisense oligonucleotides are also claimed effective to ***gene***
therapy . The method is tested in a mouse system.
ST cationic lipid DNA mucosal epithelium transfection; ***gene***
delivery liposome cationic lipid
IT Immunization
(DNA-based; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT DNA
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
(Biological use, unclassified); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(cationic lipid complexes with; construction of cationic lipid
complex-polynucleotides-contg.liposomes for ***gene***
delivery to mucosal epithelium for immunization or therapeutic
purposes)
IT Lipids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cationic; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Drug ***delivery*** systems
Gene ***therapy***
Hybridoma
Mammal (Mammalia)
Mouse
Transformation, genetic
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT Antibodies
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical
study); BIOL (Biological study); USES (Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT Antisense oligonucleotides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT Antigens
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT Lecithins
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
(Biological use, unclassified); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT ***Gene***
RL: BPR (Biological process); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(***delivery*** system; construction of cationic lipid
complex-polynucleotides-contg.liposomes for ***gene***
delivery to mucosal epithelium for immunization or therapeutic
purposes)
IT Mucous membrane
(epithelial; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Lung
(epithelium; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Drug ***delivery*** systems
(liposomes; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Antibodies
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical
study); BIOL (Biological study); USES (Uses)
(monoclonal; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Lipids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(neutral; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT Lung, disease
(treatment of; construction of cationic lipid complex-polynucleotides-
contg.liposomes for ***gene*** ***delivery*** to mucosal
epithelium for immunization or therapeutic purposes)
IT 2462-63-7, Dioleoylphosphatidylethanolamine 74524-11-1 153312-64-2,
Dmrie 158571-62-1, Lipofectamine 189203-04-1, Cellfectin
189203-05-2, ***Dmrie*** -C 212893-18-0 212893-19-1 212893-20-4
212893-21-5 212893-22-6 212893-23-7 212893-25-9 212893-26-0
212893-28-2 212893-29-3 212893-30-6 212900-70-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT 57-88-5, Cholesterol, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)
IT 4537-76-2, Distearoylphosphatidylethanolamine 104162-48-3, Dotma
144189-73-1, Dotap
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
(Biological use, unclassified); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(construction of cationic lipid complex-polynucleotides-contg.liposomes
for ***gene*** ***delivery*** to mucosal epithelium for
immunization or therapeutic purposes)

=> s DMRIE (S) DOPE and (vaccine or delivery)
154 DMRIE
4692 DOPE
1033 DOPES
5248 DOPE
(DOPE OR DOPES)
49 DMRIE (S) DOPE
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
122097 DELIVERY
1277 DELIVERIES
122908 DELIVERY
(DELIVERY OR DELIVERIES)
L21 28 DMRIE (S) DOPE AND (VACCINE OR DELIVERY)

=> dup rem 128
L28 IS NOT VALID HERE
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem l21
PROCESSING COMPLETED FOR L21
L22 28 DUP REM L21 (0 DUPLICATES REMOVED)

=> d 1-28 ti so

L22 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Prevention of myocarditis, abortion and intrauterine infection associated
with porcine circovirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L22 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Phase II study of direct intralesional gene transfer of allovectin-7, an
HLA-B7/.beta.2-microglobulin DNA-liposome complex, in patients with
metastatic melanoma
SO Clinical Cancer Research (2001), 7(8), 2285-2291
CODEN: CCREF4; ISSN: 1078-0432

L22 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Leuvectin(Vical Inc)
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2001), 2(7),
976-981
CODEN: COIDAZ

L22 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Intervesical interleukin-2 gene therapy in orthotopic mouse model of
bladder cancer
SO Keio Igaku (2001), 78(2), T177-T187
CODEN: KEIGAS; ISSN: 0368-5179

L22 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of renal cell carcinoma by intratumoral administration of an
IL-2 cDNA/ ***DMRIE*** / ***DOPE*** lipid complex
SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
CODEN: CUOTFO; ISSN: 1464-8431

L22 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Efficiency and Toxicity of Liposome-mediated Gene Transfer to Corneal
Endothelial Cells
SO Experimental Eye Research (2001), 73(1), 1-7
CODEN: EXERA6; ISSN: 0014-4835

L22 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Porcine circovirus ***vaccine***

SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L22 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Peptide-enhanced cationic lipid transfections
SO U.S., 103 pp., Cont.-in-part of U.S. 5,736,392.
CODEN: USXXAM

L22 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic
murine bladder cancer model
SO Gene Therapy (2000), 7(10), 844-851
CODEN: GETHEC; ISSN: 0969-7128

L22 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L22 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Antisense oligonucleotides increase the apoptotic effect of idarubicin in
the K-562 cell line
SO Medicina (Buenos Aires) (2000), 60(1), 143-145
CODEN: MEDCAD; ISSN: 0025-7680

L22 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Cationic lipid gene transfer of an IL-2 transgene leads to activation of
natural killer cells in a SCID mouse human tumor xenograft
SO Cellular Immunology (2000), 204(2), 96-104
CODEN: CLIMB8; ISSN: 0008-8749

L22 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of
tumor ascites and alters its cytokine profile
SO Journal of Immunology (1999), 163(12), 6378-6385
CODEN: JOIMA3; ISSN: 0022-1767

L22 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Leuvectin (Vical Inc)
SO Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs
(1999), 1(3), 324-332
CODEN: COODF2; ISSN: 1464-8466

L22 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal
immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMA3; ISSN: 0022-1767

L22 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI The use of temperature to control the size of cationic liposome/plasmid
DNA complexes
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2

L22 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Increasing the efficiency of uptake of transforming DNA complexes with
polycations using peptides
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

L22 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Immunotherapy of established tumors in mice by intratumoral injection of
interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity
SO Cancer Gene Therapy (1998), 5(5), 321-330
CODEN: CGTHEG; ISSN: 0929-1903

L22 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI ***Delivery*** of an anti-HIV-1 ribozyme into HIV-infected cells via
cationic liposomes
SO Biochimica et Biophysica Acta (1998), 1372(1), 55-68
CODEN: BBACAQ; ISSN: 0006-3002

L22 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Pulmonary surfactant inhibits cationic liposome-mediated gene
delivery to respiratory epithelial cells in vitro
SO Human Gene Therapy (1997), 8(4), 431-438
CODEN: HGTHE3; ISSN: 1043-0342

L22 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Phase I study of immunotherapy of hepatic metastases of colorectal
carcinoma by direct gene transfer of an allogeneic histocompatibility
antigen, HLA-B7
SO Gene Therapy (1997), 4(5), 419-425
CODEN: GETHEC; ISSN: 0969-7128

L22 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Intracavitary liposome-mediated p53 gene transfer into glioblastoma with
endogenous wild-type p53 in vivo results in tumor suppression and
long-term survival
SO Biochemical and Biophysical Research Communications (1997), 233(2),
359-364
CODEN: BBRCA9; ISSN: 0006-291X

L22 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Electrostatic parameters of cationic liposomes commonly used for gene
delivery as determined by 4-heptadecyl-7-hydroxycoumarin
SO Biochimica et Biophysica Acta (1997), 1329(2), 211-222
CODEN: BBACAQ; ISSN: 0006-3002

L22 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Single-vial formulations of DNA/lipid complexes
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

L22 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI A new cationic liposome DNA complex enhances the efficiency of arterial
gene transfer in vivo
SO Human Gene Therapy (1996), 7(15), 1803-1812
CODEN: HGTHE3; ISSN: 1043-0342

L22 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI ***Delivery*** of DNA-cationic liposome complexes by small-particle
aerosol
SO Human Gene Therapy (1996), 7(6), 731-741
CODEN: HGTHE3; ISSN: 1043-0342

L22 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Cancer gene therapy using plasmid DNA: safety evaluation in rodents and
non-human primates
SO Human Gene Therapy (1995), 6(5), 575-90
CODEN: HGTHE3; ISSN: 1043-0342

L22 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002 ACS
TI Safety and short-term toxicity of a novel cationic lipid formulation for
human gene therapy
SO Hum. Gene Ther. (1993), 4(6), 781-8
CODEN: HGTHE3; ISSN: 1043-0342

=>
=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 14:31:14 ON 03 SEP 2002